<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01945840</url>
  </required_header>
  <id_info>
    <org_study_id>MR/K02115X/1</org_study_id>
    <nct_id>NCT01945840</nct_id>
  </id_info>
  <brief_title>Gut Hormones and Roux en Y Gastric Bypass</brief_title>
  <official_title>Do Gut Hormones Mediate the Beneficial Effects of Roux-en-Y Bypass?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the changes in gut hormones seen following&#xD;
      Roux en Y Gastric Bypass surgery are responsible for some of the beneficial effects seen&#xD;
      post-operatively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to investigate whether chronic elevation of glucagon-like peptide-1&#xD;
      (GLP-1), oxyntomodulin and peptide YY (PYY) in combination is responsible for the majority of&#xD;
      the metabolic effects of Roux-en-Y gastric bypass (RYGB) including improved glycaemia,&#xD;
      increased energy expenditure, reduced food intake, weight loss, reduced preference for high&#xD;
      calorie foods and reduced activation in brain reward areas in response to visual food cues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Baseline - 4 weeks</time_frame>
    <description>Weight loss as measured at baseline compared to 4 weeks after infusion or diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycaemia</measure>
    <time_frame>Baseline - 4 weeks</time_frame>
    <description>As assessed by change in fructosamine and HbA1c levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Roux en Y Gastric Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gut hormone infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:&#xD;
Combination of GLP-1/OXM/PYY (GOP)&#xD;
Single GLP-1&#xD;
Single OXM&#xD;
Single PYY&#xD;
Combination of GLP-1 and OXM&#xD;
Combination of GLP-1 and PYY&#xD;
Combination of OXM and PYY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion given subcutaneously for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Very low calorie diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be asked to follow a very low calorie diet for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux en Y Gastric Bypass Surgery</intervention_name>
    <arm_group_label>Roux en Y Gastric Bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gut hormone infusion</intervention_name>
    <arm_group_label>Gut hormone infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <arm_group_label>Placebo infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Very low calorie diet</intervention_name>
    <arm_group_label>Very low calorie diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Aged 18 - 70 years.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Eligible for bariatric surgery under the NHS.&#xD;
&#xD;
          -  Diagnosed with impaired glucose regulation or type 2 diabetes, according to WHO 2011&#xD;
             criteria.&#xD;
&#xD;
          -  Those with diabetes should be stable and well controlled with either diet or one oral&#xD;
             hypoglycaemic agent.&#xD;
&#xD;
          -  HbA1c â‰¤9.0% or 74.9 mmol/mol.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  History of any medical, psychological or other condition, or use of any medications,&#xD;
             including over-the-counter products, which, in the opinion of the investigators, would&#xD;
             either interfere with the study or potentially cause harm to the volunteer.&#xD;
&#xD;
          -  Without access at home to a telephone or other factor likely to interfere with ability&#xD;
             to participate reliably in the study.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Smokers.&#xD;
&#xD;
          -  Unable to maintain adequate contraception for the duration of the study and for one&#xD;
             month afterwards.&#xD;
&#xD;
          -  History of hypersensitivity to any of the components of the subcutaneous infusions.&#xD;
&#xD;
          -  Donated blood during the preceding 3 months or intention to do so before the end of&#xD;
             the study.&#xD;
&#xD;
          -  Insulin treatment.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Any other co-morbidity that would compromise the validity of the study or the safety&#xD;
             of the participant such as heart failure, clinically apparent cardiovascular disease.&#xD;
&#xD;
          -  Volunteers on anti-coagulants such as warfarin and factor Xa inhibitors will not&#xD;
             undergo adipose tissue biopsy.&#xD;
&#xD;
          -  Unable to give informed consent.&#xD;
&#xD;
          -  Previous bariatric surgery.&#xD;
&#xD;
          -  Unable to undergo fMRI due to:&#xD;
&#xD;
               -  Claustrophobia.&#xD;
&#xD;
               -  Pacemaker, metal implant, clips, implanted device, shrapnel or bullet, metal in&#xD;
                  eyes that precludes magnetic resonance imaging.&#xD;
&#xD;
               -  Significant structural abnormality on magnetic resonance brain scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen R Bloom, FRS FRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tricia Tan, MBChB MRCP</last_name>
    <email>t.tan@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen R Bloom, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Alexiadou K, Cuenco J, Howard J, Wewer Albrechtsen NJ, Ilesanmi I, Kamocka A, Tharakan G, Behary P, Bech PR, Ahmed AR, Purkayastha S, Wheller R, Fleuret M, Holst JJ, Bloom SR, Khoo B, Tan TM. Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. BMJ Open Diabetes Res Care. 2020 Mar;8(1). pii: e001076. doi: 10.1136/bmjdrc-2019-001076.</citation>
    <PMID>32209584</PMID>
  </reference>
  <reference>
    <citation>Ilesanmi I, Tharakan G, Alexiadou K, Behary P, Alessimii H, Bovill-Taylor C, Kenkre J, Choudhury S, Doyle C, Purkayastha S, Miras A, Tsironis C, Chahal H, Bloom SR, Oliver NS, Ahmed AR, Khoo B, Tan TM. Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care. 2021 Feb;44(2):614-617. doi: 10.2337/dc20-1609. Epub 2020 Dec 17.</citation>
    <PMID>33334806</PMID>
  </reference>
  <results_reference>
    <citation>Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, Cuenco J, Hope D, Anyiam O, Choudhury S, Alessimii H, Poddar A, Minnion J, Doyle C, Frost G, Le Roux C, Purkayastha S, Moorthy K, Dhillo W, Holst JJ, Ahmed AR, Prevost AT, Bloom SR, Tan TM. Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care. 2019 Aug;42(8):1446-1453. doi: 10.2337/dc19-0449. Epub 2019 Jun 8.</citation>
    <PMID>31177183</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

